3 completed, 1 not yet recruiting, 1 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow LXE408: new trials by email Literature Review of LXE408 trials Research Report on LXE408
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR). LXE408, Miltefosine 50 MG Oral Capsule [Impavido], Placebo to LXE408 - Localized Cutaneous Leishmaniasis | Phase 2 | Not yet recruiting | Drugs for Neglected Diseases | 250 | 2026-06-15 | 2026-05-05 |
| A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. LXE408, Placebo, Benznidazole - Chagas Disease | Phase 2 | Recruiting | Novartis Pharmaceuticals | 130 | 2025-04-28 | 2026-10-15 |
| LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study LXE408, sodium stibogluconate, Paromomycin - Primary Visceral Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 52 | 2024-03-29 | 2025-12-18 |
| A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis LXE408, Placebo, AmBisome® - Primary Visceral Leishmaniasis | Phase 2 | Completed | Drugs for Neglected Diseases | 101 | 2022-12-27 | 2026-04-30 |
| A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects LXE408, Placebo, Iohexol - Visceral Leishmaniasis, Chagas Disease | Phase 1 | Completed | Novartis Pharmaceuticals | 88 | 2018-12-21 | 2026-09-09 |
Chagas Disease (2) · Leishmaniasis, Visceral (1)
Drugs for Neglected Diseases (3) · Novartis Pharmaceuticals (2)
Brazil (2) · United States (2) · Argentina (1) · Colombia (1) · Ethiopia (1) · India (1) · Panama (1)